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1. Introduction 
Somatostatin, first isolated from ovine hypothala- 
mic extracts [l], has been characterized as a tetradeca- 
peptide [2], and the same peptide has been obtained 
from porcine hypothalamus [3]. Somatostatin-like 
immunoreactivity and bioactivity are widely dis- 
tributed in the central nervous system and in the 
digestive tract tissues [4-71. Size heterogeneity 
described in somatostatin-like immunoreactive mate- 
rials [3,6,8,9] raised the possibility of the existence 
of prohormonal forms of this molecule [lO,l 11. 
During the purification of porcine intestinal soma- 
tostatin differences were noticed in the chromato- 
graphic behaviour of immunoreactive fractions and 
synthetic somatogtatin-14 [ 121. A novel intestinal 
peptide was then isolated and partly characterized as 
an N-terminally extended form of somatostatin [ 131. 
We report here the primary structure of this intes- 
tinal peptide which has been found to be an octacosa- 
peptide, somatostatin-28. The results establish size 
heterogeneity in the somatostatin family of peptides. 
Sequence comparison between somatostatin-28 and 
prohormones also suggest hat it may be a precursor 
of somatostatin-14. 
2. Materials and methods 
The extended form of somatostatin was obtained 
as in [ 131 except for the final purification which was 
achieved by reverse-phase high-performance liquid 
chromatography (Waters Ass. apparatus, 6000 A sol- 
vent delivery system, U6K injector, model 450 variable 
wavelength detector) using a 300 X 3.9 mm PBondapak 
ElsevierfNorth-Holland Biomedical Press 
Crs column. A 76% triethylammonium phosphate 
0.25 M (pH 3.5)/24% acetonitrile buffer was used in 
addition to the ammonium acetate/ethanol system in 
P31. 
Batches with about the same degree of purity 
according to isotachophoresis [ 131 and thin-layer 
chromatography [ 141 have been used for the struc- 
tural work. Total compositions were determined with 
a Beckman 12 1 M amino acid analyzer after hydrolysis 
at 110°C for 24 h in 6 M HCl containing 0.5% phenol. 
Tryptic digestion and separation of peptides by high- 
voltage paper electrophoresis at pH 6.5 and 1.9 was 
performed as in [ 151. 
The reduced molecule (dithiothreitol 1 gmol/ 
100 nmol peptide) was carboxymethylated with 
iodo[2-14C]acetate (5 pmol/lOO nmol peptide) in 
Tris-HCl buffer (pH 8 .15) [ 151. The carboxy- 
methylated peptide was cleaved with cyanogen 
bromide (900 mg) in 70% formic acid, and the 
resultant material was fractionated by gel filtration 
on Sephadex G-25 (1.5 X 100 cm in 30% acetic acid). 
N-terminal amino acid analysis was performed by 
the dansyl method [ 161, and dansyl amino acids were 
identified on polyamide layers [ 171 in four solvent 
systems [ 15 ,161. Sequential degradations were carried 
out in a Beckman 890C sequencer using a 0.1 M 
quadrol peptide program in the presence of polybrene 
and with two different systems of detection of liberated 
residues [ 181. Phenylthiohydantoin derivatives were 
analyzed on a Hewlett-Packard 1084B high-perfor- 
mance liquid chromatograph, using a 250 X 4.6 mm 
RP-8 column; 10 pm particle size (Hewlett-Packard). 
Gradient elution of PTH amino acids was obtained by 
increasing acetronitrile from 24-45% in 0.01 M 
sodium acetate (pH 4.5) [ 191. Identification was also 
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performed by thin-layer chromatography on silica gel 
with fluorescent indicator. After a 45 min migration 
in xylene/isopropanol(7/2 ,v/v) and drying, amino acid 
derivatives were detected under ultraviolet light and 
subsequently stained with collidine-ninhydrin [20]. 
3. Results 
3.1. Total composition 
Results from amino acid analysis of hydrolysates 
of both oxidized and reduced carboxymethylated 
intestinal big somatostatin are given in table 1. Trypto- 
phan recovery was low in these analyses but hydrolysis 
with 4 M methane sulfonic acid clearly demonstrated 
the presence of this residue. Hydrolytic losses, and 
possibly minor contaminants, can account for the 
small deviations from integer values that are observed 
in the analytical figures. 
The data suggest hat the larger form of somato- 
statin is a peptide composed of 28 residues. 
3.2. Structural analysis 
Three different preparations of -100 nmol of the 
elongated somatostatin were analyzed in a liquid- 
phase sequencer. Two batches were reduced and 
[r4C]carboxymethylated prior to analysis. The results 
are shown in fig.1, together with the whole structure 
of the molecule, and with the data obtained for differ- 
ent tryptic and CNBr fragments. When the 14C-labelled 
peptide was analyzed, the radioactivity was recovered 
in cycles 17 and 28. The corresponding extracts con- 
tained -lo-fold increase in radioactivity above the 
background values in other cycles. The repetitive yield 
in initial steps was 96% but fell considerably after 
cycle 15. 
The novel part of the structure was further proven 
by partial sequence determinations of the isolated 
CNBr fragments (CBl, CB2) obtained after cleavage 
at the methionine in position 8 (fig.1). Radioactivity 
from the [r4C]carboxymethylation was recovered in 
cycle 9 of CB2, as expected. Apart from the ordinary 
CNBr fragments, a peptide derived from a tryptophan 
cleavage (CB3; fig.1) was also detected. 
A tryptic digest of the peptide was separated into 
5 components by high voltage paper electrophoresis 
at pH 6.5. The somatostatin-14 part accounted for 
two peptides (T4, T5, fig.1). Among the 3 extra frag- 
ments, one was highly basic (T3; free lysine), one was 
neutral (T2; proven as Glu-Arg by both total compo- 
Table 1 
Total composition of intestinal somatostatin-28 
Residue Acid hydrolysis 
After performic 
acid oxidation 
After reduction and 
carboxymethylation 
Sum of sequence 
determinations 
CYS 2.0a 
Asx 2.9 
Thr 1.9 
Ser 2.7 
Glx 0.9 
Pro 1.8 
GlY 1.2 
Ala 3.9 
Met 0.8b 
Phe 3.3 
TIP 
3:2 LYS 
Arg 2.1 
Sum 
a Cysteic acid 
b Methionine sulfone 
’ Carboxymethylcysteine 
2.1C 2 
3.2 3 
1.9 2 
2.8 3 
1.1 1 
2.0 2 
1.1 1 
3.9 4 
0.8 1 
2.8 3 
+ 1 
3.3 3 
2.3 2 
28 
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Fig.1. Primary structure of somatostatin-28 as deduced from the present determinations. Top line of arrows show sequencer 
determinations of the 22 first residues upon degradation of 100 nmol. Initial coupling -60%; repetitive yield 96% but falling after 
cycle 15; residue identifications by high-performance liquid chromatography (all cycles), by thin-layer chromatography (all cycles 
up to 12, except ll), and by radioactivity (cycle 17 on the carboxymethylated derivative). CBl-3 are CNBr-fragments, and Tl-5 
tryptic fragments, all analyzed as shown. Region 15-28 represents the previously known somatostatin part. 
sition and sequence analysis) and one was weakly 
basic (Tl; electrophoretic mobility -0.23 relative to 
aspartic acid). The latter was incompletely separated 
from fragment T5 but its total composition and 
partial sequence analysis are compatible with the 
structure deduced for the N-terminal region (fig.1). 
4. Discussion 
The primary structure presently determined 
establishes the reported partial characterization of 
the isolated intestinal molecule [ 131 as an N-terminally 
extended form of somatostatin. However, the exten- 
Table 2 
Sequence comparisons of regions preceding cleavage sites at dibasic structures in known proforms 
of peptide hormones 
Proform Position from cleavage site 
-5 -4 -3 -2 -1 
Gastrin-34 (porcine) Asp Pro Ser Lys Lys 
Proglucagon (porcine) Met Asn Thr Lys Arg 
Proinsulin (porcine) 
C-A site Pro Pro Gin Lys Arg 
B-C site Pro Lys Ala Arg Arg 
Proparathyrin (bovine) Ser Val Lys Lys Arg 
Lipotropin (porcine) 
site 36-40 Ala Ala Glu Lys Lys 
site 56-60 Pro Lys Asp Lys Arg 
Somatostatin-28 (porcine) Pro Arg Glu Arg Lys 
Structures from [ 221 and this work 
Resulting fragment with 
the N-terminus at the 
position following - 1 
Gastrin-17 
Large glucagon fragment 
Insulin A-chain 
C-peptide 
Parathyrm 
MSH 
p-Endorphin 
Somatostatin-14 
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sion is longer than previously estimated. 
The two consecutive basic residues located just 
before the cleavage site that produces somatostatin-14 
may be noticed. Such dibasic structures are of fre- 
quent occurrence in biosynthetic peptide hormone 
precursors. In the porcine intestinal somatostatin-28, 
the N-terminal extension is linked to the tetradeca- 
peptide hormone through an Arg-Lys sequence. 
Comparisons of known activation sites in pro- 
hormones are of interest. As shown in table 2, these 
sites in prohormones are largely preceded by non- 
hydrophobic residues, as in 12 I 1, often with proline 
in positions -4 or -5. It seems possible that these 
characteristics could account for the specificity of the 
activating enzymes. In any event, the structures 
suggest hat somatostatin-28 may be a prohormone 
form. The present determination furthermore con- 
firms the presence of somatostatin-like peptides in 
the gut and provides conclusive evidence of larger 
forms of somatostatin. 
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